Coherus Oncology (CHRS) vs Molecular Partners (MOLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Molecular Partners (MOLN) has outperformed Coherus Oncology (CHRS) over the past year, gaining 2.7% versus a loss of 40.9%. Over five years, MOLN leads with a -80.8% price change compared with -94.1% for CHRS. Coherus Oncology is the larger company by market cap ($156.0 million vs $145.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | MOLN |
|---|---|---|
| Share price | $1.01 | $3.81 |
| Market cap | $156.05M | $145.94M |
| 1-day change | -1.94% | +0.79% |
| YTD return | -28.87% | -12.59% |
| 1-year return | -40.94% | +2.70% |
| 5-year return | -94.06% | -80.76% |
| EPS (TTM) | $-1.25 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.62 | $5.36 |
| 52-week low | $1.01 | $3.53 |
| Distance from 52-week high | -61.39% | -28.92% |
| Average volume | 1.15M | 1.19K |
| Shares outstanding | 154.50M | 38.31M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MOLN has outperformed CHRS by 43.6 percentage points over the past year.
CHRS vs MOLN FAQ
Which is bigger, Coherus Oncology or Molecular Partners?
Coherus Oncology (CHRS) is larger, with a market capitalization of $156.05M compared with $145.94M for Molecular Partners (MOLN).
Which stock has performed better over the past year, CHRS or MOLN?
MOLN returned +2.70% over the past 12 months, compared with -40.94% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and Molecular Partners in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.